Australia markets closed

Bellicum Pharmaceuticals, Inc. (BLCM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.9900-0.0300 (-2.94%)
At close: 04:00PM EST
0.9804 -0.01 (-0.97%)
After hours: 04:27PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.0200
Open1.0000
Bid0.9000 x 800
Ask1.0600 x 900
Day's range0.9900 - 1.0300
52-week range0.9320 - 2.2000
Volume5,933
Avg. volume13,193
Market cap8.527M
Beta (5Y monthly)1.23
PE ratio (TTM)8.25
EPS (TTM)0.1200
Earnings date10 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • GlobeNewswire

    Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update

    HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update. “We are encouraged by the progress we are making in our patient enrollment efforts for the BPX-601 and BPX-603 trials despite a national fludarabine shortage, and are on track to present data updates for both programs in the first ha

  • GlobeNewswire

    Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 31, 2022. The stock options were granted as inducements material to the employees entering into employment with

  • GlobeNewswire

    Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa

    HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, CA and livestreamed globally. Details regarding Bellicum’s presentation at the conference are as follows: Event: 2022 Cell & Gene Meeting on the Mesa Date: October 11, 2022Time: 4:3